Skip to main content
. 2020 Aug 21;117(36):22351–22356. doi: 10.1073/pnas.2010229117

Fig. 4.

Fig. 4.

Effect of disrupting IL-6 signaling on PAI-1 production in severe COVID-19 patients. (A and B) Levels of 11 cytokine and chemokines (A) and PAI-1 (B) in the sera of severe COVID-19 patients. Blue indicates healthy control (HC, n = 10). Red indicates severe COVID-19 (n = 7). (C) Changes in cytokines, CRP, and PAI-1 levels in seven patients before (pre) and after (post) treatment with tocilizumab. Comparisons were made by applying a Mann‒Whitney U test followed by correction (A and B) or a paired two-tailed t test (C). Statistical comparisons are indicated; n.s.: nonsignificant.